Ocugen Licenses OCU400 to Celairis for Asia-Pacific
The exclusive deal covers Australia, New Zealand and ASEAN countries and carries up to $7.1 million in upfront and milestone payments.
Updated on Nov. 18, 2026 in Biotech

Ocugen Inc. has signed an exclusive licensing agreement with Celairis Therapeutics Holdings Pty Ltd. for its investigational gene therapy OCU400, granting commercialization rights in Australia, New Zealand and ASEAN member countries. The agreement is worth up to $7.1 million in upfront and milestone payments and marks Ocugen's third regional commercialization deal for the therapy.
Why it matters
The arrangement lets Ocugen rely on Celairis' regional regulatory and market-access capabilities rather than building its own operations in the region. The licensed territory has an estimated population of 725 million, and OCU400 has not yet received regulatory approval in any of the licensed markets.
The deal carries up to $7.1 million in upfront and milestone payments, with $6.1 million tied to the upfront payment and anticipated Phase 3 results. Ocugen receives a high-single-digit royalty on net sales and 50% of gross profits, while the outcome of the Phase 3 trial remains unknown until topline results arrive in the first quarter of 2027.
The players
Ocugen Inc.
Ocugen is a biopharmaceutical company headquartered in Malvern, Pennsylvania, developing gene therapies for inherited retinal diseases, and it is the licensor of OCU400 in this agreement.
Celairis Therapeutics Holdings Pty Ltd.
Celairis is a therapeutics company headquartered in Sydney, Australia, that will hold exclusive commercialization rights to OCU400 in the licensed Asia-Pacific territory.
The details
Under the agreement, Celairis will manage regulatory submissions, market access and commercialization across Australia, New Zealand and ASEAN member countries. OCU400 is an investigational modifier gene therapy for retinitis pigmentosa, and Ocugen is conducting the Phase 3 liMeliGhT trial. The companies also expect to enter a separate supply agreement under which Ocugen would manufacture and provide the therapy.
Timeline
Ocugen and Celairis signed the exclusive licensing agreement on November 18, 2026.
Topline results from the OCU400 Phase 3 trial are expected in the first quarter of 2027.
Roadmap
This is Ocugen's third regional commercialization agreement for OCU400, extending a partnering strategy that delegates regulatory and market-access work to local licensees while the company focuses on Phase 3 data. The structure keeps Ocugen tied to the therapy's economics through royalties and gross-profit sharing rather than through its own regional operations.
For patients with retinitis pigmentosa in the licensed markets, this deal does not change access today, since OCU400 has not received regulatory approval or registration anywhere in the territory. Any future availability will depend on Phase 3 results and on regulatory submissions that Celairis will manage in Australia, New Zealand and ASEAN countries.
The takeaway
Regional licensing lets a developer reach new markets without building local regulatory teams, but for patients the practical milestones remain the Phase 3 readout and eventual regulatory decisions. Watching the 2027 trial results will show whether the economics in this deal translate into approved therapy.
What happens next
Ocugen expects topline results from the Phase 3 liMeliGhT trial in the first quarter of 2027, and the companies expect to enter a separate supply agreement under which Ocugen would manufacture and provide OCU400.
Further reading
For more on how gene therapies move from trials toward regional markets, explore Biotech coverage on Wisevoter.
Source note: This article includes information reported by MyChesCo.



